Inrebic Webinar Episode 2

To view this email as a web page, click here.

Hurry and register to attend on September 15th, 2021, at 7pm ET

A Treatment Option for Patients with Myelofibrosis

Wednesday, September 15, 2021 • 7:00pm - 8:00pm ET

Objectives:

Clinical data supporting a treatment option for patients with intermediate-2 or high-risk myelofibrosis
NCCN Clinical Practice Guidelines surrounding use of a treatment option in myelofibrosis
Safety, adverse event management, and dose modifications

Expert insights provided by:

Ralph V. Boccia, MD, FACP

Medical Director
Center for Cancer and Blood Disorders
Chief Medical Officer, ION
Clinical Associate Professor of Medicine
Georgetown University
Washington, DC

Pursuant to the PhRMA Code on Interactions with Healthcare Professionals, attendance at this webcast program is restricted to U.S. healthcare professionals.

Bristol Myers Squibb will report transfers of value made to U.S.healthcare professionals to the extent required by federal and state laws, as applicable. To learn more about how Bristol Myers Squibb complies with the U.S. Physician Payments Sunshine Act visit https://www.bms.com/about-us/responsibility/position-on-key-issues/transparency/global-interactions-with-healthcare-professionals.html

This is a promotional program and no CME credits are offered.

Intended for specific recipient only, please do not forward or further disseminate.
© 2021 Bristol-Myers Squibb Company.
HE-US-2100140 09/21

Learn more about MJH Live Sciences products, partnerships, and solutions by visiting our website at https://www.mjhlifesciences.com/